[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,672
  • Shares Outstanding, K 14,344
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,260 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta -2.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 1
  • High Estimate $-0.28
  • Low Estimate $-0.28
  • Prior Year $-3.16
  • Growth Rate Est. (year over year) +91.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +12.67%
on 03/31/26
2.4600 -31.30%
on 04/16/26
-0.0400 (-2.31%)
since 03/27/26
3-Month
1.5000 +12.67%
on 03/31/26
2.9330 -42.38%
on 01/29/26
-1.1000 (-39.43%)
since 01/28/26
52-Week
1.5000 +12.67%
on 03/31/26
12.2300 -86.18%
on 10/15/25
-6.1400 (-78.42%)
since 04/28/25

Most Recent Stories

More News
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support...

TPST : 1.6900 (-1.74%)
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Adds dedicated business development leadership to support Tempest’s strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions...

TPST : 1.6900 (-1.74%)
Tempest Reports Year End 2025 Financial Results and Provides Business Update

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...

TPST : 1.6900 (-1.74%)
Tempest Therapeutics Announces Up To $6 Million Private Placement

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell...

TPST : 1.6900 (-1.74%)
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned...

TPST : 1.6900 (-1.74%)
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

100% complete response (CR) rate among all six efficacy evaluable patients Favorable safety profile with no Grade > 3 CRS or ICANS Prior investigator-initiated trial (IIT) reached median progression...

TPST : 1.6900 (-1.74%)
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally...

TPST : 1.6900 (-1.74%)
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China...

TPST : 1.6900 (-1.74%)
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics...

TPST : 1.6900 (-1.74%)
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 1.6900 (-1.74%)

Business Summary

Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 1.8200
2nd Resistance Point 1.7900
1st Resistance Point 1.7400
Last Price 1.6900
1st Support Level 1.6600
2nd Support Level 1.6300
3rd Support Level 1.5800

See More

52-Week High 12.2300
Fibonacci 61.8% 8.1311
Fibonacci 50% 6.8650
Fibonacci 38.2% 5.5989
Last Price 1.6900
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.